Article Text
Statistics from Altmetric.com
We read with a great interest the comment from Ciurea et al 1 recently published in Annals of Rheumatic Diseases about the impact of confinement measures lead by the COVID-19 pandemic on disease management of inflammatory rheumatic diseases.
In their study, they analysed the data from an e-cohort of patients with inflammatory rheumatism, included in a Swiss National Registry and using an app to assess drug adherence and disease activity during the Swiss confinement period. We report here the results of a survey performed on patients followed in a French e-cohort of patients with rheumatoid arthritis (RA) during the first French confinement period.
Since February 2020, France has been hardly hit by the COVID-19 pandemic, leading to national confinement between 17 March and 11 May. During this period, the population was forced to stay indoors, except for essential activities (food shopping, running,…). Also, when they were forced to go out, they were encouraged to respect isolation measures: keep 1-metre distance between each other and washing hand frequently and respiratory hygiene (coughing into the elbow, use disposable tissues). At that time, the use of the mask was not recommended except in symptomatic patients (mandatory in public transport since 11 May …
Footnotes
Correction notice This article has been corrected since it published Online First. The acknowledgement section has been updated.
Contributors AR-W and RS were responsible for the conception of the study, management of the study, data analysis, data interpretation and manuscript writing. They had access to all the data. M-ET, AB and MS were responsible for recruitment of patients from the e-cohort and gave the final aggreement for publication.
Funding The ART Registry is supported by the French Rheumatology Society. The French Rheumatology Society received grants for conducting the ART Registry from Abbvie, Pfizer, UCB, MSD, Biogen, Sandoz, Amgen, Mylan, Fresenius Kabi, Nordic Pharma. We thank Yacin Boudali, the study coordinator.
Competing interests AR-W reports grants and personal fees from Abbvie, grants and personal fees from Pfizer, personal fees from USB, personal fees from MSD, personal fees from Roche-Chugai, personal fees from Sanofi-Aventis, personal fees from Gilead, personal fees from Mylan, personal fees from Fresenius Kabi, personal fees from Sandoz, personal fees from Amgen, personal fees from Novartis, personal fees from Lilly, personal fees from BMS, outside the submitted work. M-ET reports personal fees from Pfizer, personal fees from Abbvie, personal fees from UCB, outside the submitted work; AB reports personal fees from UCB, personal fees from LILLY, personal fees from ABBVIE, personal fees from BMS, personal fees from JANSSEN, personal fees from MSD, personal fees from NOVARTIS, during the conduct of the study. RS reports non-financial support and other from amgen, other from fresenius kabi, other from pfizer, other from roche, other from lilly, non-financial support and other from gsk, other from bms, outside the submitted work.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; internally peer reviewed.